• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Elan Corporation, plc - Product Pipeline Review - 2012 Product Image

Elan Corporation, plc - Product Pipeline Review - 2012

  • Published: May 2012
  • 106 pages
  • Global Markets Direct

Elan Corporation, plc – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Elan Corporation, plc - Product Pipeline Review - 2012” provides data on the Elan Corporation, plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Elan Corporation, plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Elan Corporation, plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Elan Corporation, plc - Brief Elan Corporation, plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Elan Corporation, plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of READ MORE >



List of Tables
List of Figures
Elan Corporation, plc Snapshot
Elan Corporation, plc Overview
Key Information
Key Facts
Emisphere Technologies, Inc. – Research and Development Overview
Key Therapeutic Areas
Emisphere Technologies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Emisphere Technologies, Inc. – Pipeline Products Glance
Emisphere Technologies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Emisphere Technologies, Inc. – Early Stage Pipeline Products
Discovery Products/Combination Treatment Modalities
Emisphere Technologies, Inc. – Drug Profiles
Beta Secretase Inhibitor
Product Description
Mechanism of Action
R&D Progress
ELND005
Product Description
Mechanism of Action
R&D Progress
Gamma Secretase Research
Product Description
Mechanism of Action
R&D Progress
Parkinson's Research
Product Description
Mechanism of Action
R&D Progress
Tysabri Subcutaneous
Product Description
Mechanism of Action
R&D Progress
Emisphere Technologies, Inc. – Pipeline Analysis
Emisphere Technologies, Inc. – Pipeline Products by Therapeutic Class
Emisphere Technologies, Inc. – Pipeline Products By Target
Emisphere Technologies, Inc. – Pipeline Products by Route of Administration
Emisphere Technologies, Inc. – Pipeline Products By Mechanism of Action
Emisphere Technologies, Inc. – Recent Pipeline Updates
Emisphere Technologies, Inc. - Dormant Projects
Emisphere Technologies, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
ELND002
ELND006
ELND007
Emisphere Technologies, Inc. – Company Statement
Emisphere Technologies, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Emisphere Technologies, Inc. - Key Manufacturing Facilities
Emisphere Technologies, Inc., Recent Developments
Emisphere Technologies, Inc.- Press Release
May 14, 2012: Transition Announces ELND005 Presentations At 12th International Stockholm/Springfield Symposium On Advances In Alzheimer Therapies
Apr 26, 2012: Transition Presents Data On ELND-005 At AAN Annual Meeting
Dec 15, 2009: Elan Corporation And Transition Therapeutics Announces Phase II Study Modifications Of ELND005 For The Treatment Of Alzheimer's Disease
Dec 10, 2009: Janssen Announces Phase III Study Demonstrates INVEGA SUSTENNA Statistically Similar To RISPERDALCONSTA Long-Acting Injection
Jul 13, 2009: Elan and Transition Therapeutics Announces Phase 1 Data Of ELND005
Apr 23, 2009: Elan And Transition Therapeutics Receive Key Patent For Alzheimer's Disease Treatment With ELND005
Apr 23, 2009: Elan Corporation, plc's Scyllo-Inositol (ELND005) Therapy Receives Fast-Track Review Status For Treating Alzheimer’s Disease.
Financial Deals Landscape
Elan Corporation, plc, Deals Summary
Elan Corporation, plc, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
FeRx Secures $15 Million In Series D Financing
Partnerships
University of Cambridge Enters Into Joint Venture Agreement With Elan
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan
Elan Enters Into Collaboration With Pharma Product Development
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Elan Corporation Amends Its Collaboration With Transition Therapeutics
PharmatrophiX Enters Into Co-Development Agreement With Elan
Circ Pharma Enters Into Co-Development Agreement With Elan
Graffinity Pharma Enters Into Research Agreement With Elan
Azur Pharma Enters Into Co-Development Agreement With Elan
Elan Enters Into Co-Development Agreement With Transition Therapeutics
Archemix Enters Into Research And Development Agreement With Elan
Strand Genomics Enters Into Agreement With Elan Pharma
MAP Pharma Extends Co-Development Agreement With Elan
Licensing Agreements
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan
Ariadne Enters Into Licensing Agreement With Elan Pharma
Zogenix Enters Into Licensing Agreement With Elan
GeneGo Enters Into Licensing Agreement With Elan Pharma
Amarin Enters Into Licensing Agreement With Elan
Nitromed Enters Into Licensing Agreement With Elan Pharma
Elan And AstraZeneca Enter Into Licensing Agreement With Abbott
EntreMed Enters Into Licensing Agreement With Elan
Elan Enters Into Licensing Agreement With Roche
Biogen Idec And Elan Enter Into Licensing Agreement With Genentech
Elan Pharma Enters Into Licensing Agreement With Roche
Equity Offering
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million
Elan Completes Private Placement Of $885 Million
Allergy Therapeutics Completes Private Placement Of $27 Million
Debt Offering
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million
Elan Completes Debt Offering Of Senior Notes For $150 Million
Elan Completes Debt Offering Of 8.875% Senior Notes For $465 Million
Elan Completes Public Offering Of 7.75% Senior Fixed Rate Notes For $850 Million
Asset Transactions
Azur Pharma Acquires PRIALT From Elan Pharma
Johnson & Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan
Eisai Acquires European Rights To Prialt From Elan
Acorda Therapeutics Acquires US Rights Of Zanaflex From Elan
Elan Sells Myobloc Rights To Solstice Neurosciences
Eisai Acquires Rights To Zonegran From Elan
Merrion Pharma Acquires Drug Delivery Technologies From Elan
Acquisition
Elan Sells Minority Stake In Warner Chilcott
Isis Acquires Orasense and HepaSense From Elan
Depomed Acquires Depomed Development From Elan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Elan Corporation, plc, Key Information
Elan Corporation, plc, Key Facts
Emisphere Technologies, Inc. – Pipeline by Indication, 2012
Elan Corporation, plc – Pipeline by Stage of Development, 2012
Elan Corporation, plc – Monotherapy Products in Pipeline, 2012
Emisphere Technologies, Inc. – Phase II, 2012
Emisphere Technologies, Inc. – Discovery, 2012
Elan Corporation, plc – Pipeline By Therapeutic Class, 2012
Elan Corporation, plc - Pipeline By Target, 2012
Elan Corporation, plc – Pipeline By Route of Administration, 2012
Elan Corporation, plc – Pipeline Products By Mechanism of Action, 2012
Emisphere Technologies, Inc. – Recent Pipeline Updates, 2012
Emisphere Technologies, Inc. - Dormant Developmental Projects,2012
Emisphere Technologies, Inc. - Discontinued Pipeline Products, 2012
Elan Corporation, plc, Subsidiaries
Elan Corporation, plc, Key Manufacturing Facilities
Elan Corporation, plc, Deals Summary
FeRx Secures $15 Million In Series D Financing
University of Cambridge Enters Into Joint Venture Agreement With Elan
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan
Elan Enters Into Collaboration With Pharma Product Development
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim
Elan Corporation Amends Its Collaboration With Transition Therapeutics
PharmatrophiX Enters Into Co-Development Agreement With Elan
Circ Pharma Enters Into Co-Development Agreement With Elan
Graffinity Pharma Enters Into Research Agreement With Elan
Azur Pharma Enters Into Co-Development Agreement With Elan
Elan Enters Into Co-Development Agreement With Transition Therapeutics
Archemix Enters Into Research And Development Agreement With Elan
Strand Genomics Enters Into Agreement With Elan Pharma
MAP Pharma Extends Co-Development Agreement With Elan
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan
Ariadne Enters Into Licensing Agreement With Elan Pharma
Zogenix Enters Into Licensing Agreement With Elan
GeneGo Enters Into Licensing Agreement With Elan Pharma
Amarin Enters Into Licensing Agreement With Elan
Nitromed Enters Into Licensing Agreement With Elan Pharma
Elan And AstraZeneca Enter Into Licensing Agreement With Abbott
EntreMed Enters Into Licensing Agreement With Elan
Elan Enters Into Licensing Agreement With Roche
Biogen Idec And Elan Enter Into Licensing Agreement With Genentech
Elan Pharma Enters Into Licensing Agreement With Roche
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million
Elan Completes Private Placement Of $885 Million
Allergy Therapeutics Completes Private Placement Of $27 Million
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million
Elan Completes Debt Offering Of Senior Notes For $150 Million
Elan Completes Debt Offering Of 8.875% Senior Notes For $465 Million
Elan Completes Public Offering Of 7.75% Senior Fixed Rate Notes For $850 Million
Azur Pharma Acquires PRIALT From Elan Pharma
Johnson & Johnson Acquires Assets And Rights To Alzheimer’s Immunotherapy Program From Elan
Eisai Acquires European Rights To Prialt From Elan
Acorda Therapeutics Acquires US Rights Of Zanaflex From Elan
Elan Sells Myobloc Rights To Solstice Neurosciences
Eisai Acquires Rights To Zonegran From Elan
Merrion Pharma Acquires Drug Delivery Technologies From Elan
Elan Sells Minority Stake In Warner Chilcott
Isis Acquires Orasense and HepaSense From Elan
Depomed Acquires Depomed Development From Elan

List of Figures
Elan Corporation, plc – Pipeline by Indication, 2012
Elan Corporation, plc – Pipeline by Stage of Development, 2012
Elan Corporation, plc – Monotherapy Products in Pipeline, 2012
Elan Corporation, plc – Pipeline By Therapeutic Class, 2012
Elan Corporation, plc – Pipeline By Route of Administration, 2012
Elan Corporation, plc - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS